Literature DB >> 34031031

Correspondence on 'Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort'.

Giuseppe A Ramirez1,2, Emanuel Della-Torre3,2, Luca Moroni3,2, Mona-Rita Yacoub3,2, Lorenzo Dagna3,2.   

Abstract

Entities:  

Keywords:  COVID-19; autoimmune diseases; immune system diseases; vaccination

Year:  2021        PMID： 34031031     DOI： 10.1136/annrheumdis-2021-220539

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  3 in total

1.  COVID-19 vaccine safety and nocebo-prone associated hesitancy in patients with systemic rheumatic diseases: a cross-sectional study.

Authors:  George E Fragoulis; Vassiliki-Kalliopi Bournia; Eugenia Mavrea; Gerasimos Evangelatos; Kalliopi Fragiadaki; Anastasios Karamanakos; Eyrydiki Kravariti; Katerina Laskari; Stylianos Panopoulos; Maria Pappa; Dimos D Mitsikostas; Maria G Tektonidou; Dimitrios Vassilopoulos; Petros P Sfikakis
Journal:  Rheumatol Int       Date:  2021-11-05       Impact factor: 2.631

Review 2.  Pemphigus during the COVID-19 Epidemic: Infection Risk, Vaccine Responses and Management Strategies.

Authors:  Xueyi Huang; Xiaoqian Liang; Jiao Zhang; Hang Su; Yongfeng Chen
Journal:  J Clin Med       Date:  2022-07-08       Impact factor: 4.964

3.  Reactogenicity and immunogenicity of the second COVID-19 vaccination in patients with inborn errors of immunity or mannan-binding lectin deficiency.

Authors:  Lisa Göschl; Daniel Mrak; Katharina Grabmeier-Pfistershammer; Karin Stiasny; Helmuth Haslacher; Lisa Schneider; Thomas Deimel; Felix Kartnig; Selma Tobudic; Daniel Aletaha; Heinz Burgmann; Michael Bonelli; Winfried F Pickl; Elisabeth Förster-Waldl; Clemens Scheinecker; Matthias Gerhard Vossen
Journal:  Front Immunol       Date:  2022-09-14       Impact factor: 8.786
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.